DR. ELAINE M YEE MD
Prescription History 1720006802
Internal Medicine - Infectious Disease in Reno, NV

NPI Status: Active since July 17, 2006

Contact Information

75 PRINGLE WAY
SUITE 705
RENO, NV
ZIP 89502
Phone: (775) 329-0333
Fax: (775) 329-6954

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ELAINE M YEE MD, an active Infectious Disease specialist practicing in Reno, NV. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 174 documented patient claims. Among these therapy options, the most frequently utilized medication is Doxycycline Hyclate, which accounts for 66 claims alone.


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.5
Days Supply 671
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply236
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $509.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.84

State Avg Cost Per Claim

$13.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cefadroxil

Generic Formulation: CefadroxilSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 510
NV State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply210
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $408.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.39

State Avg Cost Per Claim

$11.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cephalexin

Generic Formulation: CephalexinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 32
30-Day Fills 36.0
Days Supply 1,060
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.2
Peer Average Days Supply315
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $321.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.04

State Avg Cost Per Claim

$10.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dovato

Generic Formulation: Dolutegravir Sodium/LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NV State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills81.5
Peer Average Days Supply2,444
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.4% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,473.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,861.25

State Avg Cost Per Claim

$2,820.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: dolutegravir and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 66
30-Day Fills 88.0
Days Supply 2,527
NV State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply429
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 144.4% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,688.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.74

State Avg Cost Per Claim

$22.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 42.2
Days Supply 1,146
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply346
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.5% more claims than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $600.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.69

State Avg Cost Per Claim

$5.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ELAINE M YEE MD provides transparency into local medical care patterns within Reno, NV.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.